Medplus Health Services Intrinsic Value
Medplus Health Services (MEDPLUS) median intrinsic value is ₹822.92 from 9 valuation models (range ₹195–₹1623), vs current price ₹649.30 — +26.7% upside (Trading Below Calculated Value), margin of safety 21.1%. Read MEDPLUS dividend yield for the complete payout history and dividend yield track record.
MEDPLUS Valuation Methods Summary — DCF, Graham Number & P/E
Medplus Health Services intrinsic value across 9 models vs current price ₹649.30 — upside/downside and value range per method. For current market price and key ratios, visit Medplus Health Services stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹255.84 | ₹204.67 - ₹307.01 | -60.6% | EPS: ₹21.32, Sector P/E: 12x |
| Book Value Method | asset | ₹822.92 | ₹740.63 - ₹905.21 | +26.7% | Book Value/Share: ₹822.92, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹1298.60 | ₹1168.74 - ₹1428.46 | +100.0% | Revenue/Share: ₹3141.67, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹1298.60 | ₹1168.74 - ₹1428.46 | +100.0% | EBITDA: ₹760.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹1623.25 | ₹1298.60 - ₹1947.90 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹194.79 | ₹175.31 - ₹214.27 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹194.79 | ₹175.31 - ₹214.27 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹1280.00 | ₹1152.00 - ₹1408.00 | +97.1% | ROE: 13.0%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹628.29 | ₹565.46 - ₹691.12 | -3.2% | EPS: ₹21.32, BVPS: ₹822.92 |
MEDPLUS Intrinsic Value vs Market Price — All Valuation Models
Medplus Health Services fair value range ₹195–₹1623 vs current market price ₹649.30 across 9 valuation models. Analyse Medplus Health Services shareholding analysis to track promoter, FII and institutional holdings.
MEDPLUS Intrinsic Value Analysis — Undervalued or Overvalued?
Medplus Health Services median intrinsic value ₹822.92, current price ₹649.30 — Trading Below Calculated Value by 26.7%, margin of safety 21.1%.
What is the intrinsic value of MEDPLUS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Medplus Health Services (MEDPLUS) is ₹822.92 (median value). With the current market price of ₹649.30, this represents a +26.7% variance from our estimated fair value.
The valuation range spans from ₹194.79 to ₹1623.25, indicating ₹194.79 - ₹1623.25.
Is MEDPLUS undervalued or overvalued?
Based on our multi-method analysis, Medplus Health Services (MEDPLUS) appears to be trading below calculated value by approximately 26.7%.
MEDPLUS Financial Health — Key Ratios vs Industry Benchmarks
Medplus Health Services financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.63 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 13.0% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 9.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.92x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
MEDPLUS Cash Flow Quality — Operating & Free Cash Flow
Medplus Health Services operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹496 Cr | ₹432 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹540 Cr | ₹381 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹144 Cr | ₹103 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹90 Cr | ₹90 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹170 Cr | ₹-182 Cr | Positive Operating Cash Flow | 6/10 |